WALTHAM, Mass. -- (BUSINESS WIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, reported today that it will exhibit at the American Diabetes Association’s (ADA) 74th Scientific Sessions. The ADA Scientific Sessions will be held on June 13-17 in San Francisco at the Moscone Center.
NeuroMetrix, led by its President and Chief Executive Officer, Shai N. Gozani, M.D., Ph.D., will feature the SENSUS™ Pain Management System designed for people suffering from painful diabetic neuropathy (PDN). This comfortable and wearable technology utilizes non-invasive stimulation of sensory nerves to deliver a fast-acting, drug free option for pain relief. The device is lightweight and can be worn during the day while remaining active, or at night while sleeping. PDN is one of the most common causes of chronic pain and affects up to 5 million people in the U.S. alone. SENSUS is marketed in the U.S. by DJO Global and by regional distributors.
DPNCheck® will also be featured. This rapid and quantitative point-of-care test allows physicians to accurately detect diabetic peripheral neuropathy (DPN), even at very early stages. DPN is the most common complication of diabetes, affecting over half of people with diabetes. DPN causes significant morbidity including loss of sensation, pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers which may require lower extremity amputations. DPNCheck is directly marketed by NeuroMetrix in the U.S. and by Omron Healthcare in the major markets of Asia.
The Company’s scientific advisory board representing international leaders in the detection, management, and treatment of the neurological complications of diabetes will meet at the ADA Scientific Sessions.
Attendees are encouraged to visit NeuroMetrix at booth #1237.
NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The Company has a major focus on diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The Company markets the SENSUS device for treating chronic pain, focusing on physicians managing patients with neuropathic pain such as painful diabetic neuropathy. The Company also markets DPNCheck, which is a rapid, accurate, and quantitative point-of-care test for peripheral neuropathies such as diabetic neuropathy. This product is used to detect neuropathies at an early stage and to guide treatment. For more information, please visit http://www.NeuroMetrix.com.